Business Context and Reporting Period
Cocrystal Pharma, Inc. filed this Form 8-K on August 6, 2018, to report the results of its 2018 Annual Meeting of Shareholders held on the same date. The company is incorporated in Delaware and operates from Tucker, Georgia.
Key Financial Metrics
This filing is a current report regarding shareholder voting results and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
Shareholders voted on four proposals at the Annual Meeting. The results were as follows:
- Proposal 1 (Election of Directors): All six nominees (Raymond Schinazi, Gary Wilcox, David Block, Phillip Frost, Jane Hsiao, and Steven Rubin) were elected. Votes ranged from approximately 18.33 million to 18.36 million "For" each nominee.
- Proposal 2 (Reduction of Authorized Shares): Shareholders approved an amendment to reduce the authorized common stock from 800,000,000 to 100,000,000 shares. The vote was 21,493,793 "For" versus 32,953 "Against".
- Proposal 3 (Executive Compensation): Shareholders approved the advisory vote on named executive officer compensation with 18,339,109 "For" votes versus 17,175 "Against".
- Proposal 4 (Ratification of Auditors): Shareholders ratified the appointment of BDO USA, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018. The vote was 21,532,486 "For" versus 12,440 "Against".
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the procedural outcomes of the shareholder meeting.
Investor Verification Checklist
- Verify the effective date of the amendment reducing authorized shares from 800 million to 100 million.
- Confirm the tenure of the newly elected board members until the next annual meeting.
- Review the definitive proxy statement filed on June 25, 2018, for detailed context on the executive compensation and auditor ratification.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.